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Following the publication of this article, the authors noted an error
in the data reported.
One patient in the AML-D11 study (showing negativity for both
FCM-MRD and GATA1-MRD) was incorrectly reported dead after
relapse following a data input error. After re-confirming the
survival data for all other patients, the dataset has been updated
and results are as follows.
● The number of patients who relapsed was decreased from 7 to 6.
● The 3-year event-free survival (EFS) and overall survival (OS)
rates in the entire population (n= 78) were 88.5 and 91.0%.
● The 3-year EFS and OS rates in the SR patients (n= 76) were
90.8 and 93.4%.
● The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-
MRD-negative population, and 60.0 and 80.0% in the positive
population.
● Three-year EFS and OS rates were both 98.1% in the GATA1-
MRD-negative population, and 57.1 and 71.4% in the positive
population.
● The adjusted hazard ratios for the association of FCM-MRD
with EFS and OS were 14.67 (95% CI, 2.00–107.79; p= 0.01)
and 13.48 (0.81–224.27; p= 0.07), respectively, while multi-
variate analysis of GATA1-MRD did not converge in the
updated dataset due to the limited number of events in the
GATA1-MRD-negative population.
Table 2, Supplementary Table 4, and Figs. 3 and 4 have been
corrected and are shown below.
The conclusions of the article remain unchanged.
Table 2. Multivariate Cox regression of FCM-MRD for event-free and overall survivals in the standard risk population.
EFS OS
HR 95% CI p HR 95% CI p
Analysis of FCM-MRD (N= 65, including five MRD-positive patients)
MRD at Time point 2
Negative Ref Ref
Positive 14.67 2.00–107.79 0.01 13.48 0.81–224.27 0.07
Cytogenetics
Other abnormalities Ref Ref
1q loss 6.03 0.53–69.21 0.15 10.68 0.67–170.88 0.09
Platelet (per 1010/L increase) 1.09 0.87–1.37 0.45 0.95 0.65–1.37 0.77
MRD minimal residual disease, EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval.
Multivariate analysis of GATA1-MRD did not converge due to the limited number of events in the GATA1-MRD-negative population.
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Table S4. Univariate Cox regression of prognostic factors for event-free and overall survivals among 78 patients.
EFS OS
HR 95% CI p HR 95% CI P
Age at diagnosis ≥ 24 months 4.71 1.05–21.07 0.04 5.28 0.88–31.61 0.07
Girl 0.81 0.18–3.64 0.79 1.71 0.29–10.22 0.56
Mosaic 21 trisomy 3.56 0.65–19.42 0.14 7.32 1.03–52.05 0.05
History of TAM 0.52 0.12–2.31 0.39 0.45 0.08–2.72 0.39
Cardiac complication 0.71 0.13–3.90 0.70 0.36 0.05–2.55 0.31
FAB classification
M1 18.24 2.04–163.20 0.01 Not estimable
M7 1.68 0.38–7.49 0.50 3.51 0.59–20.99 0.17
RAEB-T 1.28 0.25–6.57 0.77 2.10 0.35–12.60 0.41
RAEB 0.23 0.03–1.95 0.18 Not estimable
RA Not estimable Not estimable
White blood cells (per 106/L increase) 1.00 1.00–1.00 0.38 1.00 1.00–1.00 0.55
Hemoglobin (per 1-g/dL increase) 0.81 0.61–1.08 0.16 0.86 0.61–1.21 0.39
Platelet (per 1010/L increase) 1.08 0.92–1.27 0.36 1.04 0.85–1.28 0.68
Cytogenetics
Normal karyotype 0.54 0.06–4.60 0.57 Not estimable
Monosomy 7 Not estimable Not estimable
Monosomy 7 (complex) 1.92 0.22–16.47 0.55 3.59 0.37–34.55 0.27
Sole trisomy 8 Not estimable Not estimable
Complex 1.78 0.21–15.23 0.60 2.83 0.29–27.23 0.37
1q loss 6.11 1.12–33.39 0.04 12.41 1.75–88.28 0.01
7p loss 1.35 0.16–11.60 0.78 2.18 0.23–20.97 0.50
Acquired +21 Not estimable Not estimable
Others 1.44 0.29–7.15 0.65 1.41 0.20–10.01 0.73
GATA1 mutation 7.03 0.84–58.88 0.07 Not estimable
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